Loading...
A multicenter, open-label, phase III study of Abcertin in Gaucher disease
BACKGROUND: Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. METHODS: The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve...
Na minha lista:
| Udgivet i: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5690733/ https://ncbi.nlm.nih.gov/pubmed/29137040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000008492 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|